--- title: 'Director, Sourcing & Procurement - R&D Clinical Operations and Supplies at Summit Therapeutics' canonical: 'https://feeny.ai/job/director-sourcing-procurement-r-d-clinical-operations-and-supplies-summit-1ctpcgpnyv4w' type: 'job' last_seen: '2026-10-16' --- # Director, Sourcing & Procurement - R&D Clinical Operations and Supplies at Summit Therapeutics - **Company:** Summit Therapeutics - **Location:** United States - **Compensation:** $190k–$237k - **Work type:** remote - **Posted:** 2026-10-14 - **Last confirmed live:** 2026-10-16 - **Apply:** https://job-boards.greenhouse.io/summittherapeutics/jobs/4452526009 ## Job description About Summit: Summit Therapeutics Inc. is a biopharmaceutical oncology company with a mission focused on improving quality of life, increasing potential duration of life, and resolving serious unmet medical needs. At Summit, we believe in building a team of world class professionals who are passionate about this mission, and it is our people who drive this mission to reality. Summit’s core values include integrity, passion for excellence, purposeful urgency, collaboration, and our commitment to people. Our employees are truly the heart and soul of our culture, and they are invaluable in shaping our journey toward excellence. Summit’s team is inspired to touch and help change lives through Summit’s clinical studies in the field of oncology. Summit has multiple global Phase 3 clinical studies, including: Non-small Cell Lung Cancer (NSCLC) - HARMONi: Phase 3 clinical study which was intended to evaluate ivonescimab combined with chemotherapy compared to placebo plus chemotherapy in patients with EGFR-mutated, locally advanced or metastatic non-squamous NSCLC who were previously treated with a 3rd generation EGFR TKI. - HARMONi-3: Phase 3 clinical study which is intended to evaluate ivonescimab combined with chemotherapy compared to pembrolizumab combined with chemotherapy in patients with first-line metastatic NSCLC. - HARMONi-7: Phase 3 clinical study which is intended to evaluate ivonescimab monotherapy compared to pembrolizumab monotherapy in patients with first-line metastatic NSCLC. Colorectal Cancer (CRC) - HARMONi-GI3: Phase 3 clinical study intended to evaluate ivonescimab in combination with chemotherapy compared with bevacizumab plus chemotherapy. Ivonescimab is an investigational therapy not presently approved by any regulatory authority other than China’s National Medical Products Administration (NMPA). Summit is headquartered in Miami, Florida, and has additional offices in California, New Jersey, the UK, and Ireland. ## Overview of Role The Director, Sourcing & Procurement – R&D Clinical Operations and Supplies will serve as business partner supporting sourcing strategy, contracting, and governance activities across Summit’s Clinical Operations organization and global clinical trial portfolio. This individual will report to the Head of Procurement. The role is responsible for supporting the selection, contracting, and oversight of key clinical service providers, including CROs, central laboratories, imaging vendors, eCOA and other eClinical technology providers, patient recruitment and retention suppliers, investigator payment providers, specialty service vendors, and clinical trial supply partners. The position may also support clinical supply and logistics-related procurement activities, helping ensure the timely and cost-effective delivery of materials and services required to execute global clinical studies. The breadth of this role provides significant exposure across the end-to-end clinical development lifecycle and the opportunity to influence sourcing strategy, supplier performance, and operational execution across the clinical portfolio. Working closely with Clinical Operations, R&D, Clinical Supply Chain, Finance, Legal, and other cross-functional stakeholders, this individual will help drive vendor strategy, optimize study-related spending, improve sourcing and contracting processes, mitigate supplier risks, and establish effective governance models with critical suppliers. As Summit continues to grow and expand its clinical development portfolio, this role will have opportunities to support additional R&D and Commercial procurement categories and contribute to broader procurement transformation, process improvement, and vendor management initiatives across the organization. ## Role And Responsibilities - Serve as a lead/procurement business partner to Clinical Operations, providing strategic sourcing and commercial guidance throughout study planning, startup, execution, and closeout. - Develop and execute category and supplier strategies across Clinical Operations, Clinical Trial Supplies, and related R&D categories, balancing quality, compliance, service continuity, speed, and total cost. - Lead end-to-end competitive sourcing activities across CROs, central laboratories, imaging, eCOA and eClinical technology, IRT/RTSM, patient recruitment and retention, investigator payments, specialty clinical services, logistics, and clinical trial supply vendors. - Partner with Clinical Operations, R&D, and Clinical Supply Chain to translate study requirements, timelines, enrollment assumptions, and supply needs into effective sourcing plans and fit-for-purpose vendor solutions. - Provide commercial insights, market intelligence, benchmarking, bid analysis, and supplier recommendations to support study feasibility, budgeting, vendor selection, and executive decision-making. - Lead negotiation and review of MSAs, SOWs, work orders, rate cards, pricing models, service levels, and other commercial terms in collaboration with Legal, Finance, and business stakeholders. - Support financial oversight of outsourced clinical services by reviewing study budgets, change orders, scope modifications, forecasts, and supplier invoices to improve cost transparency, challenge unsupported charges, and identify savings or cost-avoidance opportunities. - Establish and facilitate vendor governance for strategic clinical and supply partners, including business reviews, performance scorecards, KPIs and SLAs, issue escalation, risk mitigation, and continuous improvement plans. - Proactively identify and help resolve supplier risks affecting study execution, including performance concerns, capacity constraints, timeline impacts, supply continuity, logistics dependencies, quality events, and contract compliance. - Contribute as a procurement generalist to broader enterprise priorities, including process standardization, sourcing tools, spend analytics, supplier rationalization, AI and automation projects, and other procurement transformation initiatives. ## Experience, Education and Specialized Knowledge and Skills - Minimum BA/BS degree or relevant graduate degree preferred - Minimum of 10+ years of experience in a Procurement/Vendor Management or Finance environment in a pharmaceutical, CRO/ biotech company or worked in a clinical R&D operations setting with a CRO/Sponsor company - Good understanding of the drug development R&D process is important - In-depth understanding of clinical trial-related execution of large global studies, including CROs, central labs, imaging, drug supply, CMC vendors, and ancillary suppliers. Oncology experience preferred. - Strong knowledge of GCP, ICH, and regulatory expectations governing outsourced clinical activities - Demonstrated ability to multi-task, prioritize, and independently solve problems in a rapidly changing environment - Proficient user of standard MS Office suite (e.g., Word, Excel), experience using electronic document management systems (e.g. Veeva Vault, etc.), and document review tools desirable - Strong computer and database skills and experience with procurement or contract management systems (e.g., Ariba, Coupa, etc.) - Attention to detail, accuracy and confidentiality with clear and concise oral and written communication skills - Excellent organizational skills - Critical thinking, problem solving, ability to work independently - Demonstrated ability to collaborate cross-functionally, manage competing priorities, and operate in a fast-paced, high growth organization This is the pay for this position Pay Transparency $190,000—$237,000 USD Actual compensation packages are based on several factors that are unique to each candidate, including but not limited to skill set, depth of experience, certifications, and specific work location. This may be different in other locations due to differences in the cost of labor. The total compensation package for this position may also include bonus, stock, benefits and/or other applicable variable compensation. Summit does not accept referrals from employment businesses and/or employment agencies in respect of the vacancies posted on this site. All employment businesses/agencies are required to contact Summit’s Talent Acquisition team at recruiting@smmttx.com to obtain prior written authorization before referring any candidates to Summit. Summit Therapeutics Inc. is an Equal Opportunity Employer and takes pride in creating and maintaining diverse environment. We do not discriminate in recruitment, hiring, training or promotion or any other employment practices for reasons of race, color, religion, gender, national origin, age, sexual orientation, marital or veteran status, disability, or any other legally protected status. ## About Summit Therapeutics ## Company Overview - **One-liner**: Summit Therapeutics Inc. is a biopharmaceutical oncology company focused on discovering, developing, and commercializing novel bispecific antibody therapies, with its lead candidate ivonescimab targeting PD-1 and VEGF for multiple solid tumors. - **Entity Type**: Public (NASDAQ: SMMT) - **Headquarters**: Miami, Florida, USA (with additional offices in Palo Alto, CA; Princeton, NJ; Oxford, UK; and Dublin, Ireland) - **Founded**: 2003 - **Founders**: Not publicly disclosed on the company website; the company was founded in 2003. ## Core Business - **Primary industry**: Biopharmaceuticals / Oncology - **Target customers**: B2B (healthcare providers, patients, and caregivers) with a focus on resolving serious unmet medical needs in oncology - **Mission statement**: "To resolve serious, unmet medical needs for the betterment of overall human health." [smmttx.com](https://smmttx.com/company/about-us/default.aspx) ## Products & Services - **Ivonescimab (SMT112)**: A novel, potential first-in-class investigational bispecific antibody targeting both PD-1 and VEGF. It is designed to combine immunotherapy (PD-1 blockade) with anti-angiogenesis (VEGF blockade) into a single molecule. Currently being studied in several global Phase 3 clinical trials for non-small cell lung cancer (NSCLC), colorectal cancer (CRC), and head and neck squamous cell carcinoma (HNSCC). Licensed from Akeso, Inc. (HKEX: 9926.HK) for territories including the U.S., Canada, Europe, Japan, Latin America, the Middle East, and Africa. [smmttx.com](https://smmttx.com/pipeline/default.aspx) ## Market Standing - **Valuation/Market Cap**: Approximately $2.7 billion (as of recent data) [linkedin.com](https://www.linkedin.com/company/summit-therapeutics) - **Key Metric**: Annual revenue of approximately $705,000 (reported). The company is pre-commercialization and heavily investing in R&D. Total funding raised since IPO (2015) is not disclosed, but the company has a strong cash position from equity offerings. - **Notable Investors/Partners**: Akeso, Inc. (key licensing partner for ivonescimab). The company is publicly traded with institutional and retail investors. - **Growth Signals**: - Headcount grew 72.5% year-over-year to 244 employees. [linkedin.com](https://www.linkedin.com/company/summit-therapeutics) - Multiple global Phase 3 trials actively recruiting (HARMONi, HARMONi-3, HARMONi-7, HARMONi-GI3, ILLUMINE). - Over 4,000 patients have been treated with ivonescimab across all clinical trials globally. [smmttx.com](https://smmttx.com/pipeline/default.aspx) - Achieved Great Place to Work® Certification. [smmttx.com](https://smmttx.com/careers/careers-overview/default.aspx) ## Competitive Advantages - **Novel Mechanism**: Ivonescimab is a first-in-class bispecific antibody targeting both PD-1 and VEGF simultaneously, potentially offering superior efficacy and fewer side effects compared to combination therapies. - **Speed and Execution**: The company emphasizes "high-speed execution in commercialization" and has rapidly initiated multiple Phase 3 trials. - **Global Reach**: Licensed territories cover major markets (U.S., Canada, Europe, Japan, Latin America, Middle East, Africa) with a strong partner (Akeso) in the rest of the world. - **Strong Balance Sheet**: With a $2.7B market cap and public listing, the company has access to capital markets to fund its pipeline. ## Strategic Focus - **Current priorities**: Advancing ivonescimab through Phase 3 clinical trials across multiple solid tumor indications (NSCLC, CRC, HNSCC), with the goal of regulatory approval and commercialization. - **Future direction**: Expanding the pipeline into additional solid tumors and leveraging the bispecific platform for future therapies. The company is focused on becoming a leading oncology player. - **Near-term milestones**: Data readouts from ongoing Phase 3 trials, potential regulatory submissions, and building commercial infrastructure. ## Why Work Here - **Culture**: The company has achieved Great Place to Work® Certification, indicating a positive, supportive, and fulfilling work environment. Core values include Commitment to People, Integrity, Passion for Excellence, Purposeful Urgency, Accountability, and Collaboration. [smmttx.com](https://smmttx.com/careers/careers-overview/default.aspx) - **Work Environment**: Fast-paced, high-energy atmosphere focused on innovation and collaboration. The company emphasizes "making a significant difference in patients’ lives." - **Benefits (U.S.)**: - 401(k) with 6% employer match - Employee Stock Purchase Plan (ESPP) with 15% discount up to the annual federal limit - Flexible Spending Account - Commuter Benefit - Onsite lunch provided - **Benefits (U.K.)**: - Private Medical Insurance - Employee Assistance Program - Life Assurance Policy - Company Pension Contributions - ESPP - **Remote/Hybrid Policy**: Not explicitly stated, but multiple office locations suggest a hybrid or on-site presence is expected for many roles. - **Open Roles**: 25 active job postings (as of recent data) including Senior Director of Sales Operations, Clinical Scientists, Medical Science Liaisons, and Drug Product MSAT roles. [greenhouse.io](https://job-boards.greenhouse.io/summitherrapeutics) - **Headcount Growth**: 72.5% year-over-year growth signals a scaling organization with opportunities for career advancement. ## Sources 1. [smmttx.com - About Us](https://smmttx.com/company/about-us/default.aspx) 2. [smmttx.com - Investor Relations Overview](https://www.smmttx.com/overview/default.aspx) 3. [smmttx.com - Pipeline](https://smmttx.com/pipeline/default.aspx) 4. [smmttx.com - Careers Overview](https://smmttx.com/careers/careers-overview/default.aspx) 5. [linkedin.com - Summit Therapeutics Company Page](https://www.linkedin.com/company/summit-therapeutics) 6. [greenhouse.io - Summit Therapeutics Careers](https://job-boards.greenhouse.io/summitherrapeutics) ## Other roles at Summit Therapeutics - [Senior Principal Scientist](https://feeny.ai/job/senior-principal-scientist-summit-therapeutics-palo-alto-n0strqh510r6) — Palo Alto, CA - [Associate Director, Clinical Supply Management (UK/EU)](https://feeny.ai/job/associate-director-clinical-supply-management-uk-eu-summit-therapeutics-oxford-4hve8zj7pay9) — Oxford UK Zug Switzerland Dublin, Ireland - [Associate Director, Clinical Supply Management](https://feeny.ai/job/associate-director-clinical-supply-management-summit-therapeutics-princeton-nj-mvc6azpxcvpd) — Princeton NJ US and Palo Alto CA, United States - [Regional Marketing Director](https://feeny.ai/job/regional-marketing-director-summit-therapeutics-princeton-p443zfx10fsb) — Princeton, NJ - [Director, Clinical Scientist](https://feeny.ai/job/director-clinical-scientist-summit-therapeutics-united-states-4b7fcrb9mkfb) — United States - [Senior Medical Director](https://feeny.ai/job/senior-medical-director-summit-therapeutics-united-states-6d943xf75bpx) — United States - [Senior Director, Oncology Clinical Educators](https://feeny.ai/job/senior-director-oncology-clinical-educators-summit-therapeutics-field-8pyx53adkr7g) — Field, United States - [Director, Clinical Operations Analytics & Performance Excellence](https://feeny.ai/job/director-clinical-operations-analytics-performance-excellence-summit-wqz1bgajvnrd) - [Corporate Counsel, Clinical Contracts](https://feeny.ai/job/corporate-counsel-clinical-contracts-summit-therapeutics-united-states-kr3cyb13nj9c) — United States - [Associate Director, Medical Writing](https://feeny.ai/job/associate-director-medical-writing-summit-therapeutics-remote-gq102xpjcf7z)